In today's complex health environment, payers are challenged to efficiently allocate resources while striving to improve quality of care.
In the world of high-risk obstetrics, this challenge is becoming increasingly more difficult. Preterm birth is on the rise, and 57% of the annual $10.2 billion spent on newborn care is being disproportionately consumed by the 10% of infants who are born preterm.* Such statistics make identifying the products and services that are fiscally responsible and improve the quality of patient care a necessity.
AmniSure International LLC meets this need for health plans by collecting market information, data, and society statements on the economic and clinical effectiveness of the AmniSure ROM Test. Additional information can be provided via our dossier, which can be accessed by contacting us.